Drugs facing NCE-1 in 2021

1. List of Aliqopa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7511041 BAYER HEALTHCARE Fused azole-pyrimidine derivatives
May, 2024

(1 year, 3 months from now)

USRE46856 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
Oct, 2029

(6 years from now)

US10383876 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
Mar, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636344 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts
Mar, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 14, 2022
Orphan Drug Exclusivity (ODE) Sep 14, 2024

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

NCE-1 date: September, 2021

Market Authorisation Date: 14 September, 2017

Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

2. List of Alunbrig drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9012462 TAKEDA PHARMS USA Phosphorous derivatives as kinase inhibitors
Apr, 2031

(8 years from now)

US10385078 TAKEDA PHARMS USA Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
Nov, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9273077 TAKEDA PHARMS USA Phosphorus derivatives as kinase inhibitors
May, 2029

(6 years from now)

US9611283 TAKEDA PHARMS USA Methods for inhibiting cell proliferation in ALK-driven cancers
Apr, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 28, 2022
Orphan Drug Exclusivity (ODE) May 22, 2027
New Indication (I) May 22, 2023

Drugs and Companies using BRIGATINIB ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET;ORAL

More Information on Dosage

3. List of Bevyxxa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598276 PORTOLA PHARMS INC Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Nov, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9555023 PORTOLA PHARMS INC Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Nov, 2026

(3 years from now)

US8557852 PORTOLA PHARMS INC Methods of using crystalline forms of a salt of a factor Xa inhibitor
Sep, 2028

(5 years from now)

US8987463 PORTOLA PHARMS INC Methods of synthesizing factor Xa inhibitors
Dec, 2030

(7 years from now)

US8404724 PORTOLA PHARMS INC Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
Mar, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 23, 2022

Drugs and Companies using BETRIXABAN ingredient

NCE-1 date: June, 2021

Market Authorisation Date: 23 June, 2017

Treatment: Prophylaxis of pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); Prophylaxis of venous thrombosis; Inhibiting coagulation

Dosage: CAPSULE;ORAL

More Information on Dosage

4. List of Calquence drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7459554 ASTRAZENECA Imidazopyrazine tyrosine kinase inhibitors
Nov, 2026

(3 years from now)

US9290504 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

US11059829 ASTRAZENECA Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate
Jul, 2036

(13 years from now)

CN1898240B ASTRAZENECA Imidazole And Pyrazine Type Tyrosine Kinase Inhibitor
Dec, 2014

(8 years ago)

CN1898240A ASTRAZENECA Imidazopyrazine Tyrosine Kinase Inhibitors
Dec, 2014

(8 years ago)

CN106243113A ASTRAZENECA Imidazole As Selective Btk Inhibitors And Paradiazine
Jul, 2032

(9 years from now)

CN103889987A ASTRAZENECA As An Inhibitor Of Btk-4-Imidazole And -1--- Benzamide And 4 - - Imidazo Triazine -1--- Benzamide
Jul, 2032

(9 years from now)

CN103889987B ASTRAZENECA Imidazole As Selective Btk Inhibitors And Paradiazine
Jul, 2032

(9 years from now)

CN106243113B ASTRAZENECA As A Selective Btk Inhibitor And Pyrazine
Jul, 2032

(9 years from now)

IN200601290P4 ASTRAZENECA Imidazopyrazine Tyrosine Kinase Inhibitors
Oct, 2024

(1 year, 8 months from now)

IN249666B ASTRAZENECA Imidazopyrazine Tyrosine Kinase Inhibitors
Oct, 2024

(1 year, 8 months from now)

EP1675860A2 ASTRAZENECA Imidazo[1,5-A]Pyrazines As Tyrosine Kinase Inhibitors
Oct, 2024

(1 year, 8 months from now)

EP1675860B1 ASTRAZENECA Imidazo[1,5-A]Pyrazines As Tyrosine Kinase Inhibitors
Oct, 2024

(1 year, 8 months from now)

EP3689878B1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP3689878A1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP2734522B1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP2734522A1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10239883 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
Jul, 2032

(9 years from now)

US9758524 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 31, 2022

Drugs and Companies using ACALABRUTINIB MALEATE ingredient

NCE-1 date: October, 2021

Market Authorisation Date: 03 August, 2022

Treatment: Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia; Treatment of adult patients with previously untreated small lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with small lymphocytic leukemia

Dosage: TABLET;ORAL

More Information on Dosage

5. List of Calquence drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7459554 ASTRAZENECA Imidazopyrazine tyrosine kinase inhibitors
Nov, 2026

(3 years from now)

US9290504 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

US9796721 ASTRAZENECA Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
Jul, 2036

(13 years from now)

CN1898240B ASTRAZENECA Imidazole And Pyrazine Type Tyrosine Kinase Inhibitor
Dec, 2014

(8 years ago)

CN1898240A ASTRAZENECA Imidazopyrazine Tyrosine Kinase Inhibitors
Dec, 2014

(8 years ago)

CN106243113A ASTRAZENECA Imidazole As Selective Btk Inhibitors And Paradiazine
Jul, 2032

(9 years from now)

CN103889987A ASTRAZENECA As An Inhibitor Of Btk-4-Imidazole And -1--- Benzamide And 4 - - Imidazo Triazine -1--- Benzamide
Jul, 2032

(9 years from now)

CN103889987B ASTRAZENECA Imidazole As Selective Btk Inhibitors And Paradiazine
Jul, 2032

(9 years from now)

CN106243113B ASTRAZENECA As A Selective Btk Inhibitor And Pyrazine
Jul, 2032

(9 years from now)

IN200601290P4 ASTRAZENECA Imidazopyrazine Tyrosine Kinase Inhibitors
Oct, 2024

(1 year, 8 months from now)

IN249666B ASTRAZENECA Imidazopyrazine Tyrosine Kinase Inhibitors
Oct, 2024

(1 year, 8 months from now)

EP1675860A2 ASTRAZENECA Imidazo[1,5-A]Pyrazines As Tyrosine Kinase Inhibitors
Oct, 2024

(1 year, 8 months from now)

EP1675860B1 ASTRAZENECA Imidazo[1,5-A]Pyrazines As Tyrosine Kinase Inhibitors
Oct, 2024

(1 year, 8 months from now)

EP3689878B1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP3689878A1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP2734522B1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP2734522A1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10239883 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
Jul, 2032

(9 years from now)

US9758524 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(11 years from now)

US10167291 ASTRAZENECA Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
Jul, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 21, 2026
New Chemical Entity Exclusivity (NCE) Oct 31, 2022
New Indication (I) Nov 21, 2022

Drugs and Companies using ACALABRUTINIB ingredient

NCE-1 date: October, 2021

Market Authorisation Date: 31 October, 2017

Treatment: Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with small lymphocytic leukemia; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia; Treatment of adult patients with previously untreated small lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab

Dosage: CAPSULE;ORAL

How can I launch a generic of CALQUENCE before it's patent expiration?
More Information on Dosage

6. List of Giapreza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10548943 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(6 years from now)

US10500247 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(6 years from now)

US9867863 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(6 years from now)

US10335451 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(6 years from now)

US9572856 LA JOLLA PHARMA Method of treating low blood pressure
Jul, 2031

(8 years from now)

US9220745 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

US10493124 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

US11096983 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

US10028995 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

US11219662 LA JOLLA PHARMA Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II
Jan, 2037

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 21, 2022

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 21 December, 2017

Treatment: Increasing blood pressure with a rate of about 20 ng/kg/min to about 40 ng/kg/min angiotensin ii in a human subject having septic shock; Increasing blood pressure with an initial rate of about 20 ng/kg/min angiotensin ii in a human subject having septic shock, and titrating the rate up.; Treating low blood pressure with angiotensin ii with an initial rate of about 5 ng/kg/min to about 20 ng/kg/min in a subject having refractory hypotension or severe hypotension, and titrating the rate up; Treating low blood pressure with angiotensin ii with an initial rate of about 5 ng/kg/min to about 20 ng/kg/min in a subject having refractory hypotension or severe hypotension; Treating refractory hypotension with about 5 ng/kg/min to about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor; Treating hypotension with about 20 ng/kg/min to about 40 ng/kg/min angiotensin ii in a human subject having septic shock; Treating refractory hypotension with about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor; Maintaining mean arterial pressure of about 65 mmhg or higher with angiotensin ii in shock patients treated with catecholamines and reducing catecholamine use; Treating high output shock with angiotensin ii by increasing mean arterial pressure in patients treated with catecholamines and reducing catecholamine use; Treating low blood pressure with angiotensin ii at an initial rate of about 20 ng/kg/min and titrating down to achieve and/or maintain a map of about 65 mm hg or above; Treating distributive shock with angiotensin ii; Treating septic shock with angiotensin ii; Maintaining mean arterial pressure of about 65 mmhg or above with about 1 ng/kg/min to about 40 ng/kg/min angiotensin ii in hypotensive patients treated with vasopressin or a vasopressin analogue and reducing vasopressin or vasopressin analogue use; Treating hypotension with angiotensin ii in a patient receiving an angiotensin converting enzyme inhibitor

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of GIAPREZA before it's patent expiration?
More Information on Dosage

7. List of Goprelto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11040032 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10857095 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10894012 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10987347 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10973811 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10933060 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10149843 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10420760 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10016407 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10231961 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10413505 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US9867815 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 14, 2022

Drugs and Companies using COCAINE HYDROCHLORIDE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 14 December, 2017

Treatment: Method for the induction of local anesthesia of the mucous membranes; Method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment; Method of administering a local anesthetic to the mucous membranes in patients with renal impairment; Method of administering a local anesthetic to the mucous membranes; Method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes; Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment; Method of administering a local anesthetic to the mucous membranes in geriatric patients

Dosage: SOLUTION;NASAL

More Information on Dosage

8. List of Idhifa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9512107 CELGENE CORP Therapeutically active compositions and their methods of use
Jan, 2033

(9 years from now)

US10093654 CELGENE CORP Therapeutically active compounds and their methods of use
Aug, 2034

(11 years from now)

US9738625 CELGENE CORP Therapeutically active compounds and their methods of use
Aug, 2034

(11 years from now)

US9732062 CELGENE CORP Therapeutically active compounds and their methods of use
Sep, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610125 CELGENE CORP Methods and compositions for cell-proliferation-related disorders
Jun, 2030

(7 years from now)

US10294215 CELGENE CORP Therapeutically active compounds and their methods of use
Jan, 2033

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 1, 2024
New Chemical Entity Exclusivity (NCE) Aug 1, 2022

Drugs and Companies using ENASIDENIB MESYLATE ingredient

NCE-1 date: August, 2021

Market Authorisation Date: 01 August, 2017

Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation

Dosage: TABLET;ORAL

More Information on Dosage

9. List of Ingrezza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8039627 NEUROCRINE Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
Apr, 2031

(8 years from now)

US10851104 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(13 years from now)

US10851103 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(13 years from now)

US10844058 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(13 years from now)

US10065952 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(13 years from now)

US10906902 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(13 years from now)

US10919892 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(13 years from now)

US10906903 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8357697 NEUROCRINE Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
Nov, 2027

(4 years from now)

US10952997 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10874648 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10857137 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10857148 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US11040029 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10993941 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10912771 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US11026939 NEUROCRINE High dosage valbenazine formulation and compositions, methods, and kits related thereto
Sep, 2038

(15 years from now)

US11311532 NEUROCRINE High dosage valbenazine formulation and compositions, methods, and kits related thereto
Sep, 2038

(15 years from now)

US11026931 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Aug, 2039

(16 years from now)

US10940141 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Aug, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 11, 2022

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 11 April, 2017

Treatment: Treatment of tardive dyskinesia; Method of administering valbenazine while avoiding concomitant use of a strong cyp3a4 inducer; Method of treating tardive dyskinesia while avoiding concomitant use of a strong cyp3a4 inducer

Dosage: CAPSULE;ORAL

How can I launch a generic of INGREZZA before it's patent expiration?
More Information on Dosage

10. List of Kisqali drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8324225 NOVARTIS Pyrrolopyrimidine compounds and their uses
Jun, 2028

(5 years from now)

US8685980 NOVARTIS Pyrrolopyrimidine compounds and their uses
May, 2030

(7 years from now)

US8415355 NOVARTIS Pyrrolopyrimidine compounds and their uses
Mar, 2031

(8 years from now)

US9193732 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9416136 NOVARTIS Pyrrolopyrimidine compounds and their uses
Aug, 2029

(6 years from now)

US8962630 NOVARTIS Pyrrolopyrimidine compounds and their uses
Dec, 2029

(6 years from now)

US9868739 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(8 years from now)

US10799506 NOVARTIS Ribociclib tablet
Apr, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 13, 2022
New Patient Population (NPP) Dec 10, 2024

Drugs and Companies using RIBOCICLIB SUCCINATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 13 March, 2017

Treatment: In combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; In combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; In combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer; In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

How can I launch a generic of KISQALI before it's patent expiration?
More Information on Dosage

11. List of Kisqali Femara Co-pack (copackaged) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8324225 NOVARTIS Pyrrolopyrimidine compounds and their uses
Jun, 2028

(5 years from now)

US8685980 NOVARTIS Pyrrolopyrimidine compounds and their uses
May, 2030

(7 years from now)

US8415355 NOVARTIS Pyrrolopyrimidine compounds and their uses
Mar, 2031

(8 years from now)

US9193732 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9416136 NOVARTIS Pyrrolopyrimidine compounds and their uses
Aug, 2029

(6 years from now)

US8962630 NOVARTIS Pyrrolopyrimidine compounds and their uses
Dec, 2029

(6 years from now)

US9868739 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(8 years from now)

US10799506 NOVARTIS Ribociclib tablet
Apr, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 13, 2022
New Patient Population (NPP) Dec 10, 2024

Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 04 May, 2017

Treatment: Treatment of pre/perimenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; As initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

How can I launch a generic of KISQALI FEMARA CO-PACK (COPACKAGED) before it's patent expiration?
More Information on Dosage

12. List of Macrilen drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6861409 NOVO Growth hormone secretagogues
Aug, 2022

(6 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8192719 NOVO Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds
Oct, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 20, 2024
New Chemical Entity Exclusivity (NCE) Dec 20, 2022

Drugs and Companies using MACIMORELIN ACETATE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 20 December, 2017

Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

13. List of Nerlynx drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7399865 PUMA BIOTECH Protein tyrosine kinase enzyme inhibitors
Dec, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7982043 PUMA BIOTECH Protein tyrosine kinase enzyme inhibitors
Oct, 2025

(2 years from now)

US9139558 PUMA BIOTECH Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
Oct, 2028

(5 years from now)

US9630946 PUMA BIOTECH Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
Oct, 2028

(5 years from now)

US10035788 PUMA BIOTECH Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
Oct, 2028

(5 years from now)

US9265784 PUMA BIOTECH Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
Aug, 2029

(6 years from now)

US9211291 PUMA BIOTECH Treatment regimen utilizing neratinib for breast cancer
Mar, 2030

(7 years from now)

US8790708 PUMA BIOTECH Coated tablet formulations and uses thereof
Nov, 2030

(7 years from now)

US8518446 PUMA BIOTECH Coated tablet formulations and uses thereof
Nov, 2030

(7 years from now)

US8669273 PUMA BIOTECH Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
Jul, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 17, 2022
New Indication (I) Feb 25, 2023
New Dosing Schedule (D) Jun 28, 2024

Drugs and Companies using NERATINIB MALEATE ingredient

NCE-1 date: July, 2021

Market Authorisation Date: 17 July, 2017

Treatment: Extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy; Use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting; Extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy

Dosage: TABLET;ORAL

How can I launch a generic of NERLYNX before it's patent expiration?
More Information on Dosage

14. List of Ozempic drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(3 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6899699 NOVO Automatic injection device with reset feature
Jan, 2022

(1 year, 1 month ago)

US8672898 NOVO Automatic injection device with reset feature
Jan, 2022

(1 year, 1 month ago)

US9486588 NOVO Automatic injection device with reset feature
Jan, 2022

(1 year, 1 month ago)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(4 months from now)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly
May, 2024

(1 year, 3 months from now)

US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(2 years from now)

US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(2 years from now)

US11446443 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(2 years from now)

US9108002 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US11311679 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US9616180 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(2 years from now)

US10376652 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(2 years from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(3 years from now)

US11097063 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(3 years from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(3 years from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(3 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(3 years from now)

US9687611 NOVO Injection device with torsion spring and rotatable display
Feb, 2027

(4 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism
Sep, 2027

(4 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(9 years from now)

US10335462 NOVO Use of long-acting GLP-1 peptides
Jun, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Jan 16, 2023
New Chemical Entity Exclusivity (NCE) Dec 5, 2022
New Dosing Schedule (D) Mar 28, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 05 December, 2017

Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof; Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of OZEMPIC before it's patent expiration?
More Information on Dosage

15. List of Parsabiv drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9278995 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Jul, 2030

(7 years from now)

US9701712 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Jul, 2030

(7 years from now)

US8377880 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Jul, 2030

(7 years from now)

US8999932 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Feb, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11162500 KAI PHARMS INC Stable liquid formulation of AMG 416 (etelcalcetide)
Jun, 2034

(11 years from now)

US10344765 KAI PHARMS INC Stable liquid formulation of AMG 416 (etelcalcetide)
Jun, 2034

(11 years from now)

US9820938 KAI PHARMS INC Stable liquid formulation of AMG 416 (etelcalcetide)
Jun, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 7, 2022

Drugs and Companies using ETELCALCETIDE ingredient

NCE-1 date: February, 2021

Market Authorisation Date: 07 February, 2017

Treatment: A method of treating secondary hyperparathyroidism (shpt)

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of PARSABIV before it's patent expiration?
More Information on Dosage

16. List of Prevymis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46791 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(1 year, 3 months from now)

US8513255 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(1 year, 3 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603384 MERCK SHARP DOHME Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
Feb, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 8, 2024
New Chemical Entity Exclusivity (NCE) Nov 8, 2022

Drugs and Companies using LETERMOVIR ingredient

NCE-1 date: November, 2021

Market Authorisation Date: 08 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

17. List of Rhopressa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9096569 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US8450344 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US10174017 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(6 years from now)

US10654844 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(6 years from now)

US8394826 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Nov, 2030

(7 years from now)

US9415043 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US10588901 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US9931336 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11021456 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US10532993 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US10882840 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US11028081 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(6 years from now)

US11185538 AERIE PHARMS INC Compositions for treating glaucoma or reducing intraocular pressure
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2022

Drugs and Companies using NETARSUDIL MESYLATE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 18 December, 2017

Treatment: Reduction of elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of RHOPRESSA before it's patent expiration?
More Information on Dosage

18. List of Rocklatan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8450344 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US9096569 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US10654844 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(6 years from now)

US10174017 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(6 years from now)

US8394826 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Nov, 2030

(7 years from now)

US9993470 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US10588901 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US9931336 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US9415043 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11021456 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US10532993 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US10882840 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US11028081 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(6 years from now)

US11185538 AERIE PHARMS INC Compositions for treating glaucoma or reducing intraocular pressure
Mar, 2034

(11 years from now)

US11197853 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2022
New Combination (NC) Mar 12, 2022

Drugs and Companies using LATANOPROST; NETARSUDIL DIMESYLATE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 12 March, 2019

Treatment: Reduction of elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ROCKLATAN before it's patent expiration?
More Information on Dosage

19. List of Rybelsus drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(3 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10086047 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Dec, 2031

(8 years from now)

US11382957 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Dec, 2031

(8 years from now)

US9278123 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Dec, 2031

(8 years from now)

US10960052 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid
Dec, 2031

(8 years from now)

US10933120 NOVO Compositions of GLP-1 peptides and preparation thereof
Mar, 2033

(10 years from now)

US10278923 NOVO Oral dosing of GLP-1 compounds
May, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
M Jan 16, 2023
New Product (NP) Sep 20, 2022
New Chemical Entity Exclusivity (NCE) Dec 5, 2022

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 20 September, 2019

Treatment: Method of treating type 2 diabetes mellitus

Dosage: TABLET;ORAL

More Information on Dosage

20. List of Rydapt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222244 NOVARTIS Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
Oct, 2022

(3 months ago)

US7973031 NOVARTIS Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
Oct, 2028

(5 years from now)

US8575146 NOVARTIS Pharmaceutical uses of staurosporine derivatives
Dec, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 28, 2022
Orphan Drug Exclusivity (ODE) Apr 28, 2024

Drugs and Companies using MIDOSTAURIN ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy; Treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl)

Dosage: CAPSULE;ORAL

How can I launch a generic of RYDAPT before it's patent expiration?
More Information on Dosage

21. List of Segluromet drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080580 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439902 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(7 years from now)

US9308204 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 19, 2022
M Sep 17, 2024

Drugs and Companies using ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 19 December, 2017

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

More Information on Dosage

22. List of Steglatro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080580 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 19, 2022
M Sep 17, 2024

Drugs and Companies using ERTUGLIFLOZIN ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 19 December, 2017

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

How can I launch a generic of STEGLATRO before it's patent expiration?
More Information on Dosage

23. List of Steglujan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(6 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(3 years from now)

US8080580 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(7 days ago)

US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(4 years from now)

US9439901 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(7 years from now)

US9308204 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 19, 2022
M Sep 17, 2024

Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 19 December, 2017

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

More Information on Dosage

24. List of Symproic drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46375 BDSI 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Oct, 2026

(3 years from now)

USRE46365 BDSI 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Jan, 2028

(4 years from now)

US9108975 BDSI Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same
Nov, 2031

(8 years from now)

US10952968 BDSI Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
May, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 23, 2022

Drugs and Companies using NALDEMEDINE TOSYLATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 23 March, 2017

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

More Information on Dosage

25. List of Trulance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7799897 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Jun, 2022

(7 months ago)

US7041786 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Jan, 2028

(4 years from now)

US10011637 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Jun, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8637451 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Mar, 2022

(10 months ago)

US9925231 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(8 years from now)

US9610321 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(8 years from now)

US9919024 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(8 years from now)

US11319346 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Mar, 2032

(9 years from now)

US9616097 SALIX Formulations of guanylate cyclase C agonists and methods of use
Aug, 2032

(9 years from now)

US11142549 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Jun, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 19, 2022

Drugs and Companies using PLECANATIDE ingredient

NCE-1 date: January, 2021

Market Authorisation Date: 19 January, 2017

Treatment: Elevation of intracellular cgmp resulting in increased intestinal fluid and accelerated transit; Chronic idiopathic constipation; Irritable bowel syndrome with constipation

Dosage: TABLET;ORAL

How can I launch a generic of TRULANCE before it's patent expiration?
More Information on Dosage

26. List of Tymlos drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748382 RADIUS HEALTH INC Method of drug delivery for bone anabolic protein
Oct, 2027

(4 years from now)

US8148333 RADIUS HEALTH INC Stable composition comprising a PTHrP analogue
Nov, 2027

(4 years from now)

US7803770 RADIUS HEALTH INC Method of treating osteoporosis comprising administration of PTHrP analog
Apr, 2031

(8 years from now)

US10996208 RADIUS HEALTH INC Abaloparatide formulations and methods of testing, storing, modifying, and using same
Apr, 2038

(15 years from now)

US11255842 RADIUS HEALTH INC Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog
Jan, 2040

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 28, 2022
M Sep 20, 2024

Drugs and Companies using ABALOPARATIDE ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: Method of treating postmenopausal women with osteoporosis at high risk for fracture.; Use for detecting neutralizing antibodies

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of TYMLOS before it's patent expiration?
More Information on Dosage

27. List of Verzenio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7855211 ELI LILLY AND CO Protein kinase inhibitors
Dec, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 28, 2022
New Patient Population (NPP) Oct 12, 2024
New Indication (I) Oct 12, 2024

Drugs and Companies using ABEMACICLIB ingredient

NCE-1 date: September, 2021

Market Authorisation Date: 28 September, 2017

Treatment: In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; In combination with fulvestrant for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy; As monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting; In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; In combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hr-positive, her2-negative, node-positive, early breast cancer at high risk of recurrence and a ki-67 score >=20%; In combination with fulvestrant for the treatment of adult patients with hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progression following endrocrine therapy; In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women, and men with hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

More Information on Dosage

28. List of Vosevi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8735372 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US9585906 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(6 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(6 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(6 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(7 years from now)

US9868745 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US8940718 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US8575135 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US8921341 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US9296782 GILEAD SCIENCES INC Inhibitors of hepatitis C virus
Jul, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8957046 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8735372

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8580765

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(6 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2029

(6 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(6 years from now)

US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(8 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(8 years from now)

US8575135

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(10 years from now)

US8940718

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(10 years from now)

US8921341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(10 years from now)

US11116783 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(10 years from now)

US11116783

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

US10912814 GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Jun, 2037

(14 years from now)

US11338007 GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Jun, 2037

(14 years from now)

US11338007

(Pediatric)

GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Dec, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 18, 2022

Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient

NCE-1 date: July, 2021

Market Authorisation Date: 18 July, 2017

Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor; Treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor

Dosage: TABLET;ORAL

More Information on Dosage

29. List of Wegovy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(3 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9764003 NOVO Use of long-acting GLP-1 peptides
Jun, 2033

(10 years from now)

US10888605 NOVO GLP-1 compositions and uses thereof
Aug, 2038

(15 years from now)

US11318191 NOVO GLP-1 compositions and uses thereof
Feb, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 5, 2022
New Product (NP) Jun 4, 2024

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 04 June, 2021

Treatment: Method for weight management according to a dose escalation schedule; Method for weight management

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

30. List of Xadago drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8278485 MDD US Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides
Jun, 2027

(4 years from now)

US8076515 MDD US Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8283380 MDD US Methods for treatment of parkinson's disease
Mar, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 21, 2022

Drugs and Companies using SAFINAMIDE MESYLATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 21 March, 2017

Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes

Dosage: TABLET;ORAL

More Information on Dosage

31. List of Xepi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6335447 FERRER INTERNACIONAL Quinolonecarboxylic acid derivatives or salts thereof
Nov, 2023

(9 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399014 FERRER INTERNACIONAL Pharmaceutical topical compositions
Dec, 2029

(6 years from now)

US9180200 FERRER INTERNACIONAL Pharmaceutical topical compositions
Jan, 2032

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 11, 2022

Drugs and Companies using OZENOXACIN ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 11 December, 2017

Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes

Dosage: CREAM;TOPICAL

More Information on Dosage

32. List of Xermelo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7553840 TERSERA 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
Dec, 2027

(4 years from now)

US8193204 TERSERA Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use
Feb, 2031

(8 years from now)

US7709493 TERSERA 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
Feb, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7968559 TERSERA Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds
Dec, 2027

(4 years from now)

US8653094 TERSERA Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use
Dec, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 28, 2022
Orphan Drug Exclusivity (ODE) Feb 28, 2024

Drugs and Companies using TELOTRISTAT ETIPRATE ingredient

NCE-1 date: February, 2021

Market Authorisation Date: 28 February, 2017

Treatment: The treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy

Dosage: TABLET;ORAL

More Information on Dosage

33. List of Zejula drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8436185 GLAXOSMITHKLINE Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
Apr, 2029

(6 years from now)

US8071623 GLAXOSMITHKLINE Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
Mar, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071579 GLAXOSMITHKLINE DNA damage repair inhibitors for the treatment of cancer
Aug, 2027

(4 years from now)

US8143241 GLAXOSMITHKLINE DNA damage repair inhibitors for treatment of cancer
Aug, 2027

(4 years from now)

US8859562 GLAXOSMITHKLINE Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Aug, 2031

(8 years from now)

US11091459 GLAXOSMITHKLINE Niraparib compositions
Mar, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 29, 2027
New Chemical Entity Exclusivity (NCE) Mar 27, 2022
New Indication (I) Apr 29, 2023

Drugs and Companies using NIRAPARIB TOSYLATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 27 March, 2017

Treatment: A method of treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer associated with homologous recombination deficiency (hrd) positive status

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in